News
QNRX
4.470
-5.30%
-0.250
Weekly Report: what happened at QNRX last week (0921-0925)?
Weekly Report · 6d ago
Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS)
TipRanks · 09/24 14:00
Quoin Pharmaceuticals Price Target Announced at $20.00/Share by Lake Street
Dow Jones · 09/23 14:32
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Benzinga · 09/23 14:23
Quoin Pharmaceuticals initiated with a Buy at Lake Street
TipRanks · 09/23 12:20
Quoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin Syndrome
NASDAQ · 09/23 06:05
Quoin Gains FDA Fast Track for QRX003 Skin Therapy
TipRanks · 09/22 20:45
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
TipRanks · 09/22 14:00
Quoin Pharmaceuticals announces U.S. FDA granted FTD to QRX003
TipRanks · 09/22 12:45
Weekly Report: what happened at QNRX last week (0914-0918)?
Weekly Report · 09/21 10:11
Quoin Pharmaceuticals registers to sell 9.37M ADRs for holders
TipRanks · 09/18 21:05
Weekly Report: what happened at QNRX last week (0907-0911)?
Weekly Report · 09/14 10:16
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/10 21:06
Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation
TipRanks · 09/10 20:33
FDA Grants Rare Pediatric Disease Designation To Quoin's QRX003 For PSS
NASDAQ · 09/08 13:47
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003
TipRanks · 09/08 13:05
FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome
Benzinga · 09/08 12:35
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Barchart · 09/08 07:30
Weekly Report: what happened at QNRX last week (0831-0904)?
Weekly Report · 09/07 10:10
Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)
TipRanks · 09/03 18:30
More
Webull provides a variety of real-time QNRX stock news. You can receive the latest news about Quoin Pharmaceuticals Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.